These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26725677)

  • 1. [In Silico Drug Design Using an Evolutionary Algorithm and Compound Database].
    Kawai K; Takahashi Y
    Yakugaku Zasshi; 2016; 136(1):107-12. PubMed ID: 26725677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo design of drug-like molecules by a fragment-based molecular evolutionary approach.
    Kawai K; Nagata N; Takahashi Y
    J Chem Inf Model; 2014 Jan; 54(1):49-56. PubMed ID: 24372539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecule evoluator. An interactive evolutionary algorithm for the design of drug-like molecules.
    Lameijer EW; Kok JN; Bäck T; Ijzerman AP
    J Chem Inf Model; 2006; 46(2):545-52. PubMed ID: 16562982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y; Mashimo T; Orita M; Ohno K; Nakamura H
    J Chem Inf Model; 2009 Apr; 49(4):925-33. PubMed ID: 19354203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-objective Genetic Algorithm for De Novo Drug Design (MoGADdrug).
    Devi RV; Sathya SS; Coumar MS
    Curr Comput Aided Drug Des; 2021; 17(3):445-457. PubMed ID: 32562528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards structure-based protein drug design.
    Zhang C; Lai L
    Biochem Soc Trans; 2011 Oct; 39(5):1382-6, suppl 1 p following 1386. PubMed ID: 21936819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
    Bermudez M; Wolber G
    Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization.
    Hartenfeller M; Proschak E; Schüller A; Schneider G
    Chem Biol Drug Des; 2008 Jul; 72(1):16-26. PubMed ID: 18564216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2007; 47(2):656-67. PubMed ID: 17315990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo drug design using multiobjective evolutionary graphs.
    Nicolaou CA; Apostolakis J; Pattichis CS
    J Chem Inf Model; 2009 Feb; 49(2):295-307. PubMed ID: 19434831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding site druggability assessment in fragment-based drug design.
    Zhou Y; Huang N
    Methods Mol Biol; 2015; 1289():13-21. PubMed ID: 25709029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EvoMD: an algorithm for evolutionary molecular design.
    Wong SS; Luo W; Chan KC
    IEEE/ACM Trans Comput Biol Bioinform; 2011; 8(4):987-1003. PubMed ID: 20876937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based de novo ligand design by multiobjective evolutionary optimization.
    Dey F; Caflisch A
    J Chem Inf Model; 2008 Mar; 48(3):679-90. PubMed ID: 18307332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided drug designing.
    Gore M; Desai NS
    Methods Mol Biol; 2014; 1168():313-21. PubMed ID: 24870144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerating two algorithms for large-scale compound selection on GPUs.
    Liao Q; Wang J; Watson IA
    J Chem Inf Model; 2011 May; 51(5):1017-24. PubMed ID: 21526799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based and fragment-based GPCR drug discovery.
    Andrews SP; Brown GA; Christopher JA
    ChemMedChem; 2014 Feb; 9(2):256-75. PubMed ID: 24353016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLIDA: GPCR-ligand database for chemical genomic drug discovery.
    Okuno Y; Yang J; Taneishi K; Yabuuchi H; Tsujimoto G
    Nucleic Acids Res; 2006 Jan; 34(Database issue):D673-7. PubMed ID: 16381956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach to local similarity of protein binding sites substantially improves computational drug design results.
    Ramensky V; Sobol A; Zaitseva N; Rubinov A; Zosimov V
    Proteins; 2007 Nov; 69(2):349-57. PubMed ID: 17623865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.